Topotecan: A new topoisomerase I inhibiting antineoplastic agent

Annals of Pharmacotherapy

Volumn 32, Issue 12, 1998, Pages 1334-1343

  Cersosimo, Robert J ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Breast; Cancer; Leukemia; Lung; Ovarian; Topotecan; Uterus

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; TOPOTECAN;

BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG CANCER; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; UTERUS CANCER;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DNA TOPOISOMERASES, TYPE I; ECONOMICS, PHARMACEUTICAL; ENZYME INHIBITORS; HUMANS; NEOPLASMS; TOPOTECAN; TREATMENT OUTCOME;

EID: 0032425604     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18049     Document Type: Review

References (8)

1. Package insert. Hycamtin (topotecan hydrochloride). Philadelphia, PA: SmithKline Beecham Co., June 1996.
2. Rivory LP, Robert J. Molecular, cellular, and clinical aspects of the pharmacology of 20 (S)-camptothecin and its derivatives. Pharmacol Ther 1995;68:269-96.
3. Herben VMM, ten Bokkel Huinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996:31:85-102.
4. Saltz L, Sirott M, Young C, Tong W, Niedzwiecki D, Tzy-Jyun Y, et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant GCSF. J Natl Cancer Inst 1993; 85:1499-1507.
5. Grochow LB, Rowinsky EK, Johnson R, Ludeman S, Kaufmann SH, McCabe FL, et al. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 1992;20:706-13.
6. Verweij J, Lund B, Beijnen J, Planting A, de-Boer-Dennert M, Koier I, et al. Phase I and pharmacokinetic study of topotecan: a new topoisomerase inhibitor. Ann Oncol 1993;4:673-8.
7. Rowinsky EK, Grochow LB, Hendricks CB, Etlinger DS, Forastiere AA, Hurowitz LA, et al. Phase I and pharmacokinetic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992;10:647-56.
8. van Warmerdam LJC, Verweij J, Schellens JHM, Rosing H, Davies BE, de-Boer-Dennert M, et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol 1995;35:237-45.